Agios Pharmaceuticals’ (AGIO) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report published on Wednesday,Benzinga reports.

AGIO has been the subject of a number of other reports. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Royal Bank of Canada upped their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Scotiabank lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Stock Down 1.1 %

Shares of Agios Pharmaceuticals stock opened at $35.42 on Wednesday. Agios Pharmaceuticals has a 12 month low of $20.96 and a 12 month high of $62.58. The business has a fifty day simple moving average of $49.94 and a 200 day simple moving average of $46.71. The stock has a market cap of $2.02 billion, a PE ratio of 3.12 and a beta of 0.80.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $97,199,000. Marshall Wace LLP increased its position in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after purchasing an additional 855,739 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $33,767,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Agios Pharmaceuticals by 66.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after buying an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at $13,922,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.